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ORIGINAL ARTICLE
INTRODUCTION
Prostate cancer (PCa) is a common disease 
with a multifactorial and complex etiology. It is 
the most common malignancy in the male and 
the second leading cause of death in many coun-
tries, including Brazil. Estimates for 2011 indicate 
that 903,500 new cases and 258,400 deaths relat-
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Objective: Extracellular matrix homeostasis is strictly maintained by a coordinated 
balance between the expression of metalloproteinases (MMPs) and their regulators. 
The purpose of this study was to investigate whether MMP-2 and its specifi c regula-
tors, TIMP-2, MT1-MMP and IL-8, are expressed in a reproducible, specifi c pattern 
and if the profi les are related to prognosis and clinical outcome of prostate cancer 
(PCa).
Materials and Methods: MMP-2, TIMP-2, MT1-MMP and IL-8 expression levels were 
analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) in freshly 
frozen malignant and benign tissue specimens collected from 79 patients with clini-
cally localized PCa who underwent radical prostatectomies. The control group con-
sisted of 11 patients with benign prostate hyperplasia (BPH). The expression profi le 
of the MMP-2 and its regulators were compared using Gleason scores, pathological 
stage, pre-operative PSA levels and the fi nal outcome of the PCa.
Results: The analysis of 79 specimens of PCa revealed that MMP-2, TIMP-2, MT1-
MMP and IL-8 were underexpressed at 60.0%, 72.2%, 62.0% and 65.8%, respec-
tively, in malignant prostatic tissue in relation to BPH samples. Considering the 
prognostic parameters, we demonstrated that high Gleason score tumors (≥ 7) over-
expressed MMP-2 (p = 0.048) and TIMP-2 (p = 0.021), compared to low Gleason 
score tumors (< 7).
Conclusion: We have demonstrated that MMP-2 and its regulators are underex-
pressed in PCa. Alternatively, overexpression of MMP-2 and TIMP-2 was related 
to higher Gleason score tumors. We postulate that alterations in metalloproteinase 
expression may be important in the control of tissue homeostasis related to prostate 
carcinogenesis and tumor behavior.
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ed to PCa will occur worldwide (1). Tumor stag-
ing, Gleason scores and PSA serum values are 
the most important prognostic factors, but even 
when used together, they cannot be used to per-
fectly diagnose patients at risk for progression 
(2). Therefore, research has been aimed to the 
identification of molecular markers that can con-
tribute to diagnosis and predict PCa progression.
 Degradation of basal membranes and ex-
tracellular matrix (ECM) is essential for tumor 
invasion and development of metastases, and 
matrix metalloproteinases (MMPs) are potent 
proteolytic enzymes that are known to play a key 
role in these processes. Within the MMP family, 
MMP2 (gelatinase A, 72 kDa) cleaves type IV col-
lagen and gelatin, which are the main structural 
components of the basal membrane (3). Expres-
sion of MMP2 has been implicated in the de-
velopment and progression of many neoplasias, 
such as bladder (4) and colon cancer (5).
MMPs are transcriptionally regulated. 
MMP2 is mainly regulated by its zymogen inhibi-
tor, tissue inhibitor of metalloproteinase 2 (TIMP2), 
and by its major activator, membrane type-1 MMP 
(MT1-MMP), also known as MMP14. MT1-MMP 
specifically activates the pro-gelatinase, MMP2, 
on the tumor cell surface in vitro through the for-
mation of a complex with TIMP2 (6). IL8 upregu-
lates MMP2 in tumor cells, which is thought to be 
responsible for its angiogenic activity (7).
Neoplasia, an imbalance between MMPs 
and their regulators, leads to excess degradation, 
which may be linked to the invasive character of 
tumor cells (8-10). The aim of the present study 
was to investigate the expression profile of MMP2 
and it specific regulators, TIMP2, MT1-MMP and 
IL8 in prostate cancer, associating them with the 
three most important prognostic parameters: Glea-
son score, pathological stage and pre-operatory 
PSA serum levels. Also, we aimed to relate these 
profiles to the outcome of patients with localized 
PCa who underwent radical prostatectomies.
MATERIALS AND METHODS
Patients
The study was conducted using surgical 
specimens from 79 patients with clinically local-
ized PCa who underwent radical prostatectomy 
in our institution between 1993 and 2007. These 
cases were randomly selected from our database. 
Patients who had undergone other adjuvant and 
neoadjuvant treatments for PCa were excluded 
from the study. All subjects provided informed 
consent to participate in the study and to allow 
their biological samples to be genetically ana-
lyzed. The Institutional Board of Ethics approved 
this study (#0453/08).
We first analyzed MMP-2, TIMP-2, MT1-
MMP and IL-8 expression levels in fresh tumor 
specimens from the 79 PCa patients using quanti-
tative real-time polymerase chain reaction (qRT-
PCR). The clinical and pathological characteristics 
of these specimens are listed in Table-1. The con-
trol group consisted of tissue specimens from 11 
patients with benign prostatic hyperplasia (BPH), 
who had lower urinary tract symptoms and had 
undergone retropubic prostatectomy (mean age 
64 ± 6.0 years).
We then correlated the expression levels 
of the genes with Gleason scores, pathological 
stage (TNM 2010) and pre-operative serum PSA 
levels (ng/mL). For analytical purposes, the path-
ological stages were described as organ-confined 
(pT2) or non-organ-confined (pT3) diseases; 
Gleason scores were classified as low grade 
(Gleason score < 7) or high grade (Gleason score 
≥ 7). Preoperative PSA levels were also used to 
identify patients at high risk (≥ 10 ng/mL) and 
low risk (< 10 ng/mL) for disease recurrence. Ad-
ditionally, we related the gene expression with 
the biochemical recurrence free survival rate in a 
mean follow-up time of 60 months, considering 
PSA levels > 0.4 ng/mL.
RNA Isolation and cDNA Synthesis
All tumor samples were obtained from 
surgical specimens and immediately frozen at 
-170º C in liquid nitrogen. A slide with a mirror 
of the frozen fragment was stained with hema-
toxylin and eosin to verify that the tumor rep-
resented at least 75% of the fragment in patients 
with cancer and to demonstrate the absence of 
tumor in those with BPH.
Total RNA was isolated with an RNAaque-
ous Kit (Applied Biosystems, CA, USA) according 
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to the manufacturer’s instructions. RNA concen-
tration was determined by measuring absorbance 
at 260/280 nM using a Nanodrop ND-1000 spec-
trophotometer (Thermo Scientific). cDNA was gen-
erated using a High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, CA, USA). The 
reactions were incubated at 25º C for 10 min., fol-
lowed by 37º C for 120 min. and 85º C for 5 min. 
The cDNA was stored at -20º C until further use.
Quantitative Real-Time PCR and Gene Expression
Expression levels of the four genes were 
analyzed by qRT-PCR using an ABI 7500 Fast 
Real-Time PCR System (Applied Biosystems). Tar-
get sequences were amplified in a 10 µL reaction 
containing 5 µL of TaqMan Universal PCR Master 
Mix, 0.5 µL of TaqMan Gene Expression Assays 
(primers and probes, see Table-2), 1 µL of cDNA 
and 3.5 µL of DNase-free water. The PCR cycling 
conditions were 2 minutes at 50º C, 10 minutes 
at 95º C, and then 40 cycles of 15 seconds at 95º 
C and 1 min at 60º C. A TaqMan B2M assay was 
used as the endogenous control (Table-2).
We used the ∆∆CT method to calculate the 
relative expression of the three target genes using 
the formula ∆∆CT = (CT target gene, PCa sample 
- CT endogenous control, PCa sample) - (CT target 
gene, BPH sample - CT endogenous control, BPH 
sample). The fold change in gene expression was 
calculated as 2-∆∆CT.
Statistical Analysis
Quantitative variables were expressed as 
median values, interquartile range (Q1-Q3), and 
minimum and maximum values. Qualitative vari-
ables were expressed as numbers and percent-
ages. To compare the clinical characteristics of 
patients with PCa, we used the Mann-Whitney, 
chi-squared and Fisher exact tests. For descrip-
tive analysis of MMP-2, TIMP-2, MT1-MMP and 
IL-8 expressions according to pathological stage, 
Gleason scores and PSA levels, we constructed 
a box plot, and for comparison between catego-
ries, we used the Mann-Whitney test. Statistical 
analysis was performed using SPSS 15.0 for Win-
dows, and significance was set at p ≤ 0.05.
Table 1 - Demographic characteristics of 79 men who underwent a radical prostatectomy treatment for prostate cancer.
Age (years)
Mean 63
Min - Max 41 – 79
PSA (ng/mL)
Mean 10.8
Min - Max 2.0 – 37.0
<10 n (%) 47 (59.5)
≥ 10 n (%) 32 (40.5)
Stage
pT2 n (%) 38 (48)
pT3 n (%) 41 (52)
Gleason Score
< 7 n (%) 33 (41.7)
 7 n (%) 46 (58.3)
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RESULTS
As shown in Figure1, the analysis of 79 
specimens of PCa revealed that MMP-2, TIMP-2, 
MT1-MMP and IL-8 were underexpressed in ma-
lignant prostatic tissue in relation  to BPH sam-
ples. MMP-2, TIMP-2, MT1-MMP and IL-8 were 
underexpressed at levels of 60.0%, 72.2%, 62.0% 
= 0.021). Only a marginal statistical difference for 
MT1-MMP was observed between the two tumor 
groups: the median was 0.89 for high-grade vs. 
0.65 for low-grade PCa (p = 0.08). There were no 
differences in the expression levels of IL-8 when 
considering Gleason scores (Table-3).
There were no differences in the expres-
sion levels of the four genes according to the 
Table 2 - Primers used in this study.
Gene symbol Assays ID
MMP2 Hs00234422_m1
TIMP2 Hs00234278_m1
MMP14 Hs00237119_m1
IL-8 Hs99999034_m1
B2M Hs99999907_m1
Figure 1 - Expression levels of the four genes in PCa tissue compared to BPH. Fold change 
in expression was calculated using the 2-∆∆CT method.
and 65.8%, respectively, in prostate cancer tissue, 
compared to benign prostate tissue.
We found differences in MMP-2 and TIMP-
2 expression between high-grade PCa (Gleason ≥ 
7) versus low-grade PCa (Gleason < 7). The medi-
an expression of MMP-2 was 0.84 for high-grade 
PCa vs. 0.52 for low-grade tumors (p = 0.048). The 
median expression of TIMP-2 was 0.59 vs. 0.39 
for high-grade and low-grade PCa, respectively (p 
pathological stage, PSA pre-operatory serum lev-
els or biochemical recurrence.
DISCUSSION
In the present study we demonstrated that 
MMP-2 and its regulators are underexpressed in 
PCa compared to BPH tissue. Others, studying dif-
ferent types of cancer, have found overexpression 
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of these genes (11,12). However, there are reports 
showing that the absence of some MMP can be 
related to the promotion of tumors. For instance, 
Balbin et al., has described an increased suscep-
tibility to skin cancer in mice that didn’t express 
MMP-8 (13). Our results are similar to those pub-
lished by Lichtinghagen et al. (2002) (14), who 
showed MMP-2 underexpression in prostate can-
cer tissue using RT-PCR. Conversely, they ob-
served higher expression of MMP-2 at the pro-
tein level using immunohistochemistry, a result 
later confirmed by Brehmer et al. (15), indicating 
that there is a discrepancy between the levels of 
MMP-2 mRNA and protein in prostate cancer.
Interestingly, we found an association be-
tween elevated expression of MMP-2 and TIMP-2 
Table 3 - Relative expression of the four genes in malignant prostatic tissue according to Gleason scores, pathological 
stages, PSA values and biochemical recurrence. Fold changes in gene expression were calculated using the ∆∆CT method 
(QRel = 2-∆∆CT).
MMP2 TIMP2 MMP14 IL8
Gleason Score
< 7 (n = 32)
0.520
(0.3-1.0)
0.391
(0.3-0.7)
0.657
(0.4-1.2)
0.839
(0.5-1.3)
≥ 7 (n = 36)
0.844
(0.4-1.4)
0.598
(0.4-1.2)
0.890
(0.5-1.7)
0.689
(0.4-1.3)
p-value 0.048 0.021 0.081 0.274
Pathological Stage
pT2 (n = 37)
0.737
(0.3-1.3)
0.493
(0.2-1.2)
0.894
(0.5-1.7)
0.767
(0.4-1.3)
pT3 (n = 40)
0.630
(0.3-1.3)
0.474
(0.3-0.7)
0.690
(0.4-1.3)
0.629
(0.4-1.3)
p-value 0.510 0.955 0.332
0.537
PSA value
< 10 (n = 45) 0.655
(0.3-1.3)
0.479
(0.3-0.9)
0.780
(0.4-1.3)
0.577
(0.3-1.2)
≥ 10 (n = 33) 0.689
(0.3-1.3)
0.482
(0.3-1.2)
0.886
(0.4-2.0)
0.767
(0.5-1.5)
p-value 0.831 0.738 0.616 0.195
Biochemical Recurrence
W/n (n = 29) 0.868
(0.4-1.1)
0.522
(0.3-0.8)
0.882
(0.5-1.2)
0.528
(0.3-1.0)
With (n = 28) 0.992
(0.4-1.5)
0.587
(0.3-1.6)
1.037
(0.5-2.2)
0.912
(0.5-1.3)
p-value 0.482 0.518 0.538 0.148
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and Gleason scores ≥ 7, while MT1-MMP, which 
was also expressed at a higher level in Gleason 
scores ≥ 7, only reached a level of marginal sta-
tistical significance (p = 0.08). The Gleason score 
is the main prognostic parameter for PCa, and it 
dictates the therapeutics in the majority of cases, 
although there are many pitfalls to use it as a de-
termining factor. Because treatment options range 
from watchful waiting to palliative androgen de-
privation, the correct characterization of histo-
logical differentiation is especially valuable for 
the correct treatment of the neoplasia. We have 
previously shown that it is possible to downgrade 
and upgrade PCa Gleason scores in radical prosta-
tectomies to values of 14% and 29%, respectively, 
showing the weakness of using it as a prognostic 
factor, even when utilized by an experienced uro-
pathologist (16). This confirms the necessity for 
additional biological information regarding PCa 
behavior. This is the first time that a study has 
shown a correlation between Gleason scores and 
MMP-2/TIMP-2 mRNA expression in PCa.
Extensive studies have revealed that ma-
lignant invasion and metastasis require ECM deg-
radation, mainly by MMPs (17). Excessive or in-
appropriate expression of MMPs may contribute 
to the pathogenesis of cancer in a wide variety 
of cases by facilitating tissue degradation. Cur-
rently, there are more than 20 identified MMPs 
that can be categorized by substrate specificity. 
Despite the clinical significance of the pathoge-
netic impact of MMPs in human cancer, including 
PCa, only a few studies of MMPs are available in 
the literature, and those mainly analyze protein 
expression (18).
Among the identified MMPs, MMP2 
cleaves type IV collagen and gelatin, which are 
the main structural components of the basal 
membrane in the ECM, and the ECM is the first 
vital barrier on the course of tumor metastasis. 
Based on these findings, MMP-2 is thought to 
contribute to matrix breakdown. Today it is clear 
that MMP-2 participates in many deregulated 
signaling pathways that are used by the tumor 
to promote cancer cell growth and angiogenesis. 
The fact that we are already aware of these at-
tributes makes MMP-2 a promising prognostic 
marker (19).
Interestingly, we found that MMP2 is un-
derexpressed in prostate cancer, indicating that 
this MMP is not related to the promotion of PCA. 
However, after the establishment of the tumor, an 
increase in expression of MMP2 may be involved 
in tumor differentiation, which explains the as-
sociation of elevated MMP2 expression in high-
grade tumors. Miyake et al. (2010) (20), using 
immunohistochemistry showed that in univari-
ate analysis MMP2 expression was significantly 
associated with biochemical recurrence, demon-
strating the importance of this gene in the pro-
gression of PCa.
At the post-translational level, MMPs are 
under the control of specific tissue inhibitors 
(TIMPs) that bind proximal to the catalytic do-
main of the MMPs, preventing substrate binding. 
TIMPs are not simply regulators of MMP activity; 
they also have multifunctional roles that include 
cell growth promotion (8) and inhibition of angio-
genesis (21). At the time of their discovery, TIMPs 
were considered to be tumor suppressor proteins. 
Increased TIMP expression is currently associated 
with decreased tumor growth, invasiveness and 
metastasis in prostate cancer and other cancer 
cell lines (22). However, the results of the current 
study demonstrate a poor prognostic significance 
of increased TIMP-2 expression, which is contrary 
to the original tumor-suppressor role that TIMPs 
were hypothesized to play. These results, how-
ever, are in agreement with recent evidence that 
supports a multifunctional and complex role for 
TIMPs. Nemeth et al. (23) described the growth-
promoting abilities of TIMP-2 in several human 
cell types, including fibroblasts, keratocytes, lym-
phocytes and stem cells. Increased TIMP1 and 
TIMP2 mRNA levels have been correlated with 
higher tumor stages, lymph node metastasis and 
shortened survival in patients with carcinoma of 
the colon (24), breast (25), or bladder (26).
Although the paradoxical positive effects of 
TIMPs on tumor progression are not completely un-
derstood, the tumor promoting activity may be due 
either to proteolytic degradation of ECM or a direct 
influence on cell survival and growth. Stimulation 
of cell growth by TIMPs is thought to be mediated 
by cAMP-dependent activation of protein Kinase A 
and increased tyrosine phosphorylation (26).
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TIMP-2 is reported to regulate matrix deg-
radation, acting through a membrane type MMP 
(MT1-MMP). MT1-MMP is a key enzyme in tumor 
angiogenesis and metastasis: it hydrolyzes a va-
riety of ECM components, and is a physiologi-
cal activator of pro-MMP-2 (27). TIMP-2 forms a 
complex with MT1-MMP on the cell surface pro-
moting hydrolysis of pro-MMP2 to its active form 
resulting in degradation of ECM.
We have shown that even with decreased 
MMP-2, TIMP-2 and MT1-MMP gene expres-
sion in cancer tissue, there was an increased ex-
pression in patients with Gleason scores ≥ 7, an 
important prognostic factor of this disease. But 
we were not able to show a correlation between 
MMP-2, TIMP-2, MT1-MMP and IL-8, and the 
outcome of the disease following a 60-month 
period of follow-up. This lack of supporting evi-
dence in this regard can be attributed to the small 
number of cases in each group.
We can postulate that the low expression 
of TIMP-2, MT1-MMP and IL-8 may be respon-
sible for the decreased MMP-2 expression in PCa 
tissue, and this profile might be a characteristic 
of prostate cancer that can be utilized for tumor 
diagnosis in the future. Also, the fact that MMP-2 
and TIMP-2 expression levels increase with tumor 
grade suggests that these genes might be involved 
in the differentiation of prostate cancer.
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